Submission of Earnings Presentation on Q2 FY27 Financial Results.

November 4, 2026 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Phiroz Jeejeebhoy Towers, Bandra Kurla Complex, Bandra (E), 25th floor, Dalal Street, MUMBAI -400 051 MUMBAI -400 001 Company Code No. AUROPHARMA Company Code No. 524804 Dear Sir / Madam, Sub: Investor / Analysts Presentation Please refer to our letter dated October 26, 2026, wherein we intimated the schedule of Investors/ Analysts call on November 5, 2026. In this connection, we enclose herewith the presentation that would be used in the said Investors / Analysts call on the Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2026. The presentation is also being uploaded to the following weblink of the Company. https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/presentations Please take the information on record. Yours faithfully, For AUROBINDO PHARMA LIMITED B. Adi Reddy Company Secretary Enclosures: as above. Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044. Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana, India Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833 Email: info@aurobindo.com Website: www.aurobindo.com Aurobindo Pharma Limited Earnings Presentation Q2FY27 Disclaimer This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma Limited, nor shall it, or any part hereof, form the basis of, or be relied on in connection with, any contract, therefore. This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward-looking statements represent our judgment and future expectations concerning the development of our business, such statements reflect various assumptions concerning future developments and a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, regulatory and legislative developments, and other key factors that we have indicated could adversely affect our business and financial performance. Aurobindo Pharma Limited undertakes no obligation to publicly revise any forward-looking statements to reflect future events or circumstances. This document is strictly confidential and may not be disclosed, reproduced or redistributed, in whole or in part, to any other person. Table of Contents 04 Q2FY27 Business & Financial Highlights 11 Financial Summary Update on Biosimilars and Biologics Contract Manufacturing 1138 Filings Snapshot Q2FY27 Business & Financial Highlights Key Financial Highlights of the Quarter Revenue EBITDA PBT Net Profit ₹ 10,263 Cr ₹ 2,156 Cr ₹ 1,691 Cr ₹ 1,124 Cr Q2FY27 ₹ 8,286 Cr ₹ 1,678 Cr ₹ 1,274 Cr ₹ 848 Cr Q2FY26 Y-o-Y 23.9% 28.5% 32.7% 32.5% growth % Business Highlights – Q2FY27 Highest ever quarterly revenue of ₹10,263 Cr with 23.9% growth Y-o-Y, driven by strong performance across all business areas Sustained strong profitability with the highest-ever quarterly EBITDA of ₹2,156 Cr at a margin of 21.0% Net Capex of US$ 89 million* primarily towards capability enhancements, new business developments Successfully completed the acquisition of Lannett further strengthening our US presence and expanding our capabilities in complex and controlled substances Generated net cash flow of US$ 146mn during the quarter, with a strong net cash position (including investments) of ~US$ 189 million* as on 30-Sep-26 Launched 10 products in the US market (including gAdvair and ADQUEYTM our first NCE) *converted at USD:INR rate as on Sep 30th, 2026 6 Quarterly Performance – Q2FY27 Revenue (₹ Cr.) EBITDA (₹ Cr.) 10,263 2,156 9,150 8,853 1,881 8,646 1,801 8,286 1,773 7,868 1,678 1,603 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 PAT (₹ Cr.) Cash flows from business (US$ Mn) 1,124 159 1,032 910 921 115 824 100 96 98 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 Q1FY26 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 Consolidated Business Performance ₹ Cr Q2FY27 Q2FY26 Y-o-Y (%) Q1FY27 Q-o-Q (%) USA 4,555 3,638 25.2% 3,770 20.8% Europe 3,161 2,480 27.5% 2,937 7.6% Growth Markets 1,026 882 16.3% 1,063 -3.5% ARV 359 325 10.2% 330 8.7% Total Formulations 9,102 7,325 24.2% 8,101 12.4% Beta-lactam 858 687 24.8% 800 7.3% Non Beta-lactam 304 273 11.3% 250 21.7% Total API 1,162 961 20.9% 1,049 10.7% Revenue from operations 10,263 8,286 23.9% 9,150 12.2% US Formulations Business Performance Highlights Revenue ex-gRevlimid (US$ Mn) Commentary • US revenue in Q2FY27 accounted for 44% of 411 consolidated revenue. Ex-gRevlimid the revenue grew by 20% Q-o-Q. The growth was driven by successful Lannett integration, strong volume gains and strong injectables ramp-up • Received final approval for 12 products during the quarter (including 1 tentative approval earlier now received final approval) Q2FY26 Q1FY27 Q2FY27 Revenue Break-up by Business Europe (EUR Mn) Growth Markets (US$ Mn) ARV (US$ Mn) API (₹ Cr.) 112 1,162 1,049 37 38 Q2FY26 Q1FY27 Q2FY27 Q2FY26 Q1FY27 Q2FY27 Q2FY26 Q1FY27 Q2FY27 Q2FY26 Q1FY27 Q2FY27 Europe business posted ARV business continued to remain API business revenues grew by Growth Markets remained stable growth of 18% YoY with strong stable with variation driven by 11% Q-o-Q driven by strong with continued momentum in key performance across all key tender opportunities performance in entire portfolio markets markets continuing its momentum Financial Summary Summary Consolidated Profit & Loss Statement ₹ Cr. Q2FY27 Q2FY26 Y-o-Y Chg. (%) Q1FY27 Q-o-Q Chg. (%) Revenue from Operations 10,263 8,286 23.9% 9,150 12.2% Gross Profit 6,280 4,947 26.9% 5,523 13.7% Gross Margin 61.2% 59.7% 149 bps 60.4% 83 bps Overheads -4,124 -3,269 26.2% -3,642 13.2% EBITDA (before Forex and Other Income) 2,156 1,678 28.5% 1,881 14.6% EBITDA Margin 21.0% 20.3% 75 bps 20.6% 45 bps Fx Gain/(Loss) 3 5 -42.8% 53 -94.6% Finance Cost -102 -95 7.3% -102 0.5% Depreciation -531 -429 23.8% -487 9.0% Other Income 165 116 43.0% 212 -21.9% Exceptional items 0 0 n/a -40 n/a PBT before share of profit / (loss) of JV 1,691 1,274 32.7% 1,517 11.5% Tax -564 -428 31.8% -483 16.7% Share of Profit/(Loss) of JV -3 2 n/a -2 92.2% Profit after Tax 1,124 848 32.5% 1,032 8.9% Minority Interest 2 0 n/a 1 n/a Net Profit attributable to Owners of the Company 1,126 848 32.7% 1,033 9.1% Reported EPS 19.57 14.61 33.9% 17.86 9.6% Average Fx rate US$1 = INR 95.55 87.29 94.53 1212 Debt Profile Gross Debt (US$ Mn) Debt as on (INR Cr) Mar-23 Mar-24 Mar-25 Mar-26 Sep-26 Closing Rate (INR/USD) 82.170 83.405 85.475 94.835 95.825 884 843 786 809 887 859 FxLoan restated in INR 4,638 3,994 5,883 6,709 7,628 Rupee Loan 224 2,324 2,065 964 604 185 117 99 84 102 Gross Debt 4,862 6,318 7,948 7,673 8,232 Cash Balance & 6,453 6,467 8,307 10,676 10,044 699 726 688 725 800 757 Investments Net Debt/(Net Cash) (1,591) (149) (359) (3,002) (1,812) Jun-25 Sep-25 Dec-25 Mar-26 Jun-26 Sep-26 Net Debt/(Net Cash) (194) (18) (42) (317) (189) (US$ Mn) Working Capital Loan Other Term Loan Finance Cost# 4.0% 5.1% 5.5% 5.0% 4.9% Net Debt Movement (US$ Mn [Showing first 8,000 characters — download PDF for full document]